SCHEMBL971700

SCHEMBL971700

Cc1ccccc1-c1nnc(S)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.49
LMNA P02545 4/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
KDM4E B2RXH2 4/20 0.43
MAPT P10636 3/20 0.43
GAA P10253 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43
STAT6 P42226 1/20 0.43
KMT2A Q03164 1/20 0.43
HIF1A Q16665 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
PTGER3 P43115 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11025136 0.81 ALDH1A1 (0.50) ALDH1A1RAB9ANPC1KDM4EMAPT
SCHEMBL21091032 0.80 ALDH1A1 (0.51) ALDH1A1LMNARAB9ANPC1KDM4E
SCHEMBL968101 0.78 KDM4E (0.61) ALDH1A1RAB9ANPC1KDM4EMAPT
SCHEMBL14424576 0.78 MAPT (0.35) ALDH1A1LMNARAB9ANPC1KDM4E
SCHEMBL970693 0.77 ALDH1A1 (0.62) ALDH1A1LMNARAB9ANPC1KDM4E
SCHEMBL22469017 0.77 GUSB (0.46) ALDH1A1RAB9AKDM4EGAAHPGD
SCHEMBL8046899 0.77 HDAC1 (0.43) ALDH1A1LMNARAB9ANPC1KDM4E
SCHEMBL11609747 0.77 ALDH1A1 (0.54) ALDH1A1LMNARAB9ANPC1KDM4E
SCHEMBL11565050 0.77 ALDH1A1 (0.49) ALDH1A1LMNARAB9ANPC1KDM4E
SCHEMBL11332564 0.77 ALDH1A1 (0.65) ALDH1A1LMNARAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110483412-B Synthetic method of rosuvastatin tert-butyl ester 安徽省庆云医药股份有限公司 2020-06-26 CN disclosed
CN-104292224-B Containing replacing 1,3,4-thiophene () diazole thioether benzothiazole amide derivatives and its preparation method and application 贵州大学 2016-07-06 CN disclosed
CN-104292224-A Benzothiazole amide derivatives containing substituted 1,3,4-thiadiazole (oxadiazole) thioether as well as preparation method and application of derivatives UNIV GUIZHOU 2015-01-21 CN disclosed
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
EP-1970377-A1 LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2008-09-17 EP disclosed
US-20070184383-A1 Photosensitive composition, photosensitive planographic printing plate material, and recording method of planographic printing plate material KONICA MINOLTA MEDICAL & GRAPHIC, INC. 2007-08-09 US disclosed
US-20070184383-A1 Photosensitive composition, photosensitive planographic printing plate material, and recording method of planographic printing plate material KONICA MINOLTA MEDICAL & GRAPHIC, INC. 2007-08-09 US disclosed
EP-0565459-B1 Novel photographic developing solution and use thereof in the high contrast development of nucleated photographic elements EASTMAN KODAK CO (US) 1998-09-16 EP disclosed
US-5457011-A Containing polyoxyalkylated phosphate ester to inhibit sludge formation EASTMAN KODAK COMPANY (US) 1995-10-10 US disclosed
US-5264323-A Hydrazine nucleation agent with developers of ascorbic acid and carbonate buffers EASTMAN KODAK COMPANY (US) 1993-11-23 US disclosed
EP-0565459-A2 Novel photographic developing solution and use thereof in the high contrast development of nucleated photographic elements EASTMAN KODAK COMPANY (US) 1993-10-13 EP disclosed
US-5236816-A Hydroquinone-free EASTMAN KODAK COMPANY (US) 1993-08-17 US disclosed
EP-0428455-A2 Photographic developing solution for use with fore-hardened X-ray films EASTMAN KODAK COMPANY (US) 1991-05-22 EP disclosed
EP-0267264-B1 HIGH CONTRAST DEVELOPMENT OF PHOTOGRAPHIC ELEMENTS EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1990-07-25 EP disclosed
EP-0267264-A1 HIGH CONTRAST DEVELOPMENT OF PHOTOGRAPHIC ELEMENTS. EASTMAN KODAK CO (US) 1988-05-18 EP disclosed
WO-1987007039-A2 HIGH CONTRAST DEVELOPMENT OF PHOTOGRAPHIC ELEMENTS EASTMAN KODAK COMPANY (US) 1987-11-19 WO disclosed
EP-0032456-B1 METHOD FOR HIGH CONTRAST DEVELOPMENT OF PHOTOGRAPHIC ELEMENTS EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1983-02-02 EP disclosed
EP-0032456-A1 Method for high contrast development of photographic elements EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1981-07-22 EP disclosed
US-4269929-A USING AN AQUEOUS ALKALINE SOLUTION CONTAINING DIHYDROXYBENZENE AND 3-PYRAZOLIDONE DEVELOPERS, A SULFITE PRESERVATIVE AND A CONTRAST-PROMOTING AMINE IN THE PRESENCE OF A HYDRAZIDE; LITHOGRAPHY EASTMAN KODAK COMPANY (US) 1981-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 ALDH1A1 2976/4885LMNA 48/4885RAB9A 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.